| 產(chǎn)品描述： | Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 μM. Hepln-13 can be used for the research of metastatic prostate cancer |
| 靶點(diǎn)： |
IC50: 0.33 μM (Hepsin);c-Met/HGFR |
| 體外研究： |
Hepln-13 (10 μM; 2 hours; 293 cells) inhibits cleavage. |
| 體內(nèi)研究： |
HepIn-13 displays dose dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes and blocks prostate cancer metastasis. |
| 參考文獻(xiàn)： |
1. Tang X, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget. 2014;5(5):1352-1362. |
| 溶解性： |
Soluble in DMSO |
| 保存條件： |
2-8℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.075 ml |
15.375 ml |
30.75 ml |
| 5 mM |
0.615 ml |
3.075 ml |
6.15 ml |
| 10 mM |
0.308 ml |
1.538 ml |
3.075 ml |
| 50 mM |
0.062 ml |
0.308 ml |
0.615 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
北京